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Aim. To assess the impact of siRNA transfection on the tumor development under experimental pathology of the
thyroid gland. Methods. Experiments were performed on rats weighing 180 ± 20 g, which were divided into five
groups: IA and IB – animals with simulated hypo- and hyperthyroid states and transplanted Guerin’s
carcinoma; IIA and IIB – animals with simulated hypo- and hyperthyroid states and transplanted Guerin’s
carcinoma in combination with siRNA transfection; III – control group with transplanted Guerin’s carcinoma in
combination with siRNA transfection. Orthogonal dimensions of the tumor were measured. Histological and im-
munohistochemical researches of tumor samples were performed.Results. It has been shown that the inhibitory
effect of short interfering RNA is realized to a greater extent in the hypothyroid state, indicating an important
role of thyroid hormones in the regulation of expression of genes that control the cell cycle. We discuss a possible
dependence of necrobiotic processes prevalence and characteristic changes in the blood vessels on the effects of
thyroid hormones on angiogenesis and proliferative processes. Conclusions. siRNA trasfection leads to in-
hibition of tumor growth in animals with both hypo- and hyperthyroidism, but it is more pronounced at
hypothyroidism.
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Introduction. Some authors consider the influence of
T-helper subpopulations and other immune cells to be
the basic mechanisms of the thyroid hormone (TH) ac-
tion along with direct stimulation of cancerogenesis [1].
Thyroxine regulates the functioning of tyrosine protein
and plays a significant role in apoptosis [2]. Thus, the
functional state of the thyroid gland is an important pre-
dictor of clinical outcome of tumors.
There has been recently detected a possibility of the
gene expression inhibition based on the creation of
double-stranded RNA (dsRNA) molecules. Using the-
se dsRNA enables target exclusion of individual genes
without violation of the formation of neighboring ge-
nes’ proteins; this method being more effective and fast
than any other. This phenomenon is called RNA interfe-
rention; the dsRNA-sequence that contributes to it is
called siRNA (short interfering RNA).
siRNA does not prevent gene readouts but includes
the typical cell mechanism blocking the transcription
of gene mRNA and prevents the formation of a corres-
ponding protein (post-transcriptional gene signalling).
Nonspecific siRNA binding with genes is an im-
portant issue for researchers and clinicians who use
them for gene expression inhibition. However, no pro-
per attention has been paid to the application of tumor
growth epigenetic modifications with thyroid dysfunc-
tion in experimental models of low-differentiated tu-
mors [3–5].
The SOCS family proteins form a]part of the classi-
cal negative feedback system that regulates cytokine
signal transduction. SOCS1 is involved in negative re-
gulation of cytokines that signal through the JAK/
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STAT3 pathway. Through binding to JAKs, SOCS1 in-
hibits their kinase activity and suppresses the Tec pro-
tein-tyrosine activity in vitro. There are known some
siRNA modulating the SOCS1 gene expression, e. g.
hsa-miR-411, hsa-miR-142-5p, hsa-miR-30c, hsa-miR-
379*, hsa-miR-331-3p, hsa-miR-548v, hsa-miR-30d,
hsa-miR-221, however their effects on the dynamics of
tumor growth in the conditions of disorders of thyroid
gland functions have been never investigated.
The aim of the study was to assess an impact of
siRNA transfection on the tumor development under ex-
perimental pathology of the thyroid gland.
Materials andmethods. Experiments were conduc-
ted on 32 white female laboratory rats weighing 180 ±
 20 g, which were kept on a vivarium standard diet.
Guerin’s carcinoma (0.5 ml suspension of tumor cells –
(5–6) 10
6 cells/ml) was transplanted to the animals of I
group (n = 12) by subcutaneous injection in the back
between the shoulders. These cells were obtained from
donor rats (tumor strain was provided by R. E. Kavetsky
Institute of Experimental Pathology, Oncology and Ra-
diobiology, NAS of Ukraine). To the animals of II group
(n = 12) the tumor cells were administered along with
siRNA transfection according to the same method [6].
Each group was divided into two subgroups (A and
B) depending on the functional state of thyroid gland.
The hypothyroid state (subgroups IA and IIA) was si-
mulated by blocking the thyroid hormones secretion by
mercazolil that was administered one time per day at a
dose of 5 mg per 100 g body weight intragastric within
two weeks. The hyperthyroid condition (subgroups IB
and IIB)wasmodeled by the L-thyroxine intragastric ad-
ministration 1 time per day at a dose of 50 mg per 100 g
body weight for two weeks. There was also assessed the
dynamics of tumor growth amongst the animals (III or
control group, n = 8) receiving siRNA without chan-
ging the functional state of thyroid gland.
To obtain the tumor suspension we preliminary se-
lected some cells of the tumor by its incubationwith col-
lagenase (with concentration 1 µl/ml) for 1 h at 37 oC.
Afterwards, an additional splitting of the tumor cells was
done with the automated system for mechanical tissue
disaggregation «BDMedimachine» (Germany). The tu-
mor cells were filtered with a syringe through the cap
Steri-Dual (3 M «Health Care» (Germany)). Next, the
cells were counted in the Goryaev’s chamber. Then
RPMI 1640 medium was added up to the concentration
of (5–6) 10
6 cells/ml. 0.5 ml of the received tumor sus-
pension was administered subcutaneously to the rats of
the Group IA and IIB.
The transfection mixture was prepared separately.
100 µl DMEM medium with high glucose concentra-
tion was added to a sterile tube with 4 µl of transfection
reagent Turbofect R-0537 («Fermentas», Lithuania) and
then the diluted transfection reagent was kept at room
temperature for 10–20 min. The diluted transfection re-
agent was added with 1 µl siRNA («Dharmacon», USA,
P-011511-07-0005 siRNA, human SOCS1). Then they
were gently stirred with a pipette, and incubated at room
temperature for 10–20 min to form transfection comple-
xes. The obtained mixture was diluted with 500 µl of cul-
ture medium RPMI 1640. Then the culture medium was
aspirated from the tumor cells and immediately repla-
cedwith amixture of the diluted reagent of transfection.
In 20–30 min the rats of Group IIA and IIB were
inoculated with the tumor cells with siRNA.
Within 21 days the development of the tumors in
the experimental rats was observed. Then animals were
decapitated under a mild chloroform anesthesia. The
specimens were stained with hematoxylin and eosin and
analyzed with optical microscope Leica DM750 (Ger-
many) with photo-video output, camera (5 M pixels).
We carried out immunohistochemical studies of
proliferationmarkerKi-67. Proliferation index was cal-
culated as the proportion of positively stained nuclei of
tumor cells within the proliferative compartment in 5
randomly selected fields of view (> 500 cells) [7, 8].
Statistical analysis was performed using the soft-
ware Statistica 6.15 («StatSoft Inc.», USA) [9].
Results and discussion. The siRNA transfection
which is the specific inhibition of endogenous genes sig-
nificantly affected the tumor growth dynamics (Table).
It could be concluded that siRNA transfection redu-
ced tumor growth in hypothyroid rats by 25.5 %, while
the tumor growth in hyperthyroid status decreased only
by 3.5 %. This makes possible to assume the thyroid
hormone ability to block siRNA inhibitory effect.
During the histological examination of tumors deri-
ved from experimental animals with simulated hypothy-
roid state it was found that the tumor areas consisted of
polymorphic cells with the signs of glandular epitheli-
um, large hyperchromatic nucleus, coarse chromatin,
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homogenous eosinophilic cytoplasm and clear outlines.
A shape of nuclei was uneven with indrawings. Tumor
cells were located separately, their nuclei were displa-
ced to the periphery. Large areas of destroyed cells with
nuclei lysis were observed among the tumor tissue, as
well as the fragments of dead cells, dramatically dystro-
phic granulocytes. Necrosis occupied approximately 1/3
of the investigated tumor area. Eosinophils dominated
over granulocytes. Outgrowth contacts with the forma-
tion of lace like structures between the tumor cells were
found in the areas with a more compact arrangement of
tumor cells. These cells had an amphiphilic cytoplasm,
their borders were uneven. A large number of capillaries
with flattened endotheliumwere observed among the tu-
mor tissue. Necrosis of tumor cells was observed in non-
vascular and pericapillary space.
After the siRNA transfection in tumor tissue of hy-
pothyroid rats, destroyed cells with nuclei lysis, cell-
shading, fibrin strands and mixed dystrophic granulo-
cytes were frequently found among the fragments of
dead cells. Necrosis of tumor cells also was observed in
non-vascular and pericapillary space (Fig. 1, see inset).
On the other hand, somewhat different picture was
observed in the hyperthyroid state. In a histological sec-
tion of the encapsulated tumor site which consisted of
large polymorphic cells with signs of glandular epithe-
lium and large hyperchromatic nucleus there were diffe-
rent variants of the nuclei location: from central to fully
displaced to the periphery. The nuclei had a coarse chro-
matin with the presence of 1–3 large nucleoli. The sha-
pe of most nuclei was smooth, concave-oval. The cells
contained homogeneous amphiphilic cytoplasm with
clear boundaries. The tumor cells were placed separate-
ly at greater area, they had a nucleus shifted to the peri-
phery. There were observed the outgrowth contacts with
the formation of lace like and perivasculary palisade li-
ke structures between the tumor cells. Among the tumor
tissue there were also found small line areas of destroy-
ed tumor cells with nuclei lysis, the fragments of necro-
tic cells mixed with sharply dystrophic granulocytes
and the fragments of necrotic granulocytes. The nec-
rosis fields occupied about 1/5 of all the investigated
tumor area. At the level of tumor cells with necrosis the-
re were a small number of isolated convex-oval tumor
cells with the eccentric rounded nucleus and eosinophi-
lic cytoplasm. There were large number of capillaries
with flattened endothelium.
After application of siRNA transfection of animal’s
tumor at hyperthyroidism we observed slightly diffe-
rent histological figure (Fig. 2, see inset). There were do-
minated the areas with relatively compact arrangement
of tumor cells with outgrowth contacts and the forma-
tion of lace like structures. The cytoplasm of tumor cells
was amphiphilic. The boundaries of cells were uneven
and with outgrowing. Parts of the nuclei had a rough
form with indrawings. Other areas consisted of separa-
tely located polymorphic cells with a large hyperchro-
mic nucleus. Nucleus was shifted to the periphery. It was
defined a coarse chromatin and a homogeneous eosino-
philic cytoplasm with clear bounds. There were also ob-
served the fields of destroyed cells with nuclei lysis, fal-
ling out of fibrin strands and admixture of dramatically
dystrophic granulocytes among the fragments of dead
cells. Besides, there were the following changes: the
compact areas of tumor cells changed to more isolated
and then to necrosis. A large number of capillaries were
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Group
Days of the experiment
9 12 15 18 21
²À 2.38 ± 0.15* 7.76 ± 0.37* 15.82 ± 0.55* 18.77 ± 0.61* 21.39 ± 0.41*
²B 2.6 ± 0.13* 6.22 ± 0.25* 12.92 ± 0.45* 17.35 ± 0.39* 19.22 ± 0.74*
²²À 1.71 ± 0.08 5.5 ± 0.15 8.02 ± 0.25* 11.41 ± 0.44 15.92 ± 0.48
²²B 1.62 ± 0.14 5.18 ± 0.17 9.5 ± 0.31 14.83 ± 0.64 18.53 ± 0.72
²II (control) 1.78 ± 0.09 5.18 ± 0.17 10.72 ± 0.41 13.5 ± 0.46 16.52 ± 0.48
Note. *The difference with the control group is statistically significant (P < 0.05).
Dynamics of tumor growth (cm3) in the experimental groups (M ± m)
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Fig. 1. Histology of the modified pathomorphosis in a hypothyroid state: a – without the siRNA transfection,  400; b – with the siRNA
transfection, 200. Hematoxylin-eosin
a b
Fig. 2. Histology of the modified pathomorphosis in a hyperthyroid state: a – without the siRNA transfection, 400; b – with siRNA transfection,
100. Hematoxylin-eosin
among the tumor, some of them had blood stasis and mi-
xed thrombi without evidence of organization. The to-
tal volume of necrosis was about 1/4 of the total tissue,
necrosis fields were larger in the depth of tumor site and
lesser – under the capsule of connective tissue. The bor-
der of the tumor with the granulation tissue was clear.
The index of tumor cells proliferation in female-
rats with simulated hypothyroidism in the group IA
was 14.4%, whereas in the group IIA it was only 5.6%.
The proliferation index has not changed after siRNA
transfection introduction in the model of experimental
hyperthyroidism: in the IB group it was 10.3 %, and in
IIB – 9.6 % (p > 0.05).
While studying oncogenesis much attention has be-
en recently paid to the signal transducer and activator
of transcription 3 (STAT3). STAT3 is classified as a
proto-oncogene because its activated form can mediate
oncogenic transformation in cells culture and induce the
formation of tumors [10]. Several studies have shown
that STAT3 is activated inmany cancers, such as leuke-
mia, gliomas, cancer of the head and neck, melanoma,
breast cancer, prostate cancer, cervical cancer, endomet-
rial cancer [11]. Tyrosine kinases Jak2, onkoprotein Src
and vascular endothelial growth factor (VEGF) are
potential activators of STAT3. Abnormally activated
STAT3 activates a number of genes which manage the
behavior of tumor cells (survival ability, growth, angio-
genesis, invasion and resistance to immune oversight).
The suppressor of cytokine signaling (SOCS1) is
one of the genes which can reduce the tyrosine kinase
activity and block Jak2 leading to the inhibition of
STAT3 phosphorylation [12]. Activation of SOCS1 is
influenced by cytokines. This gene inhibits hormonal
signals and suppresses cytokine signals acting via the
intracellular negative feedback reducing the activity of
tyrosine kinase Jak connected with the receptor [12].
There is information that siRNA also can inhibit
proliferation and increase apoptosis as a result of inter-
ruption of STAT3 phosphorylation through reducing
regulatory Jak2 activation [13]. siRNA also suppresses
the expression of VEGF, which regulates angiogenesis,
and the tumor immune response in cancer. As a result of
this interaction, the tumor cell proliferation decreases,
apoptosis and expression of both mature and immature
markers of dendritic cells (HLA-DR, CD80, CD86,
CD40, CD1a, CD83) increase [14].
Thus, the results obtained strongly prove that the tu-
mor inhibition effect of small interfering RNA takes
place to a greater extent at hypothyroid state than at hy-
perthyroidism. This phenomenon indicates an important
role of thyroid hormones in the regulation of the genes
expression, which controls the cell cycle. According to
the literature data [15], we can make an assumption that
thyroxine activates the proliferation of tumor cells mo-
re than their apoptosis. The prevalence of necrobiotic
processes and characteristic changes in the blood vessels
may be associated with the specific effects of thyroid
hormones on angiogenesis.
In addition to the gene expression inhibition, one
more interesting property of siRNA is the ability to trig-
ger independently an immune response – to activate al-
pha- and beta-interferons, cytokines and other media-
tors of inflammation [16].
So, besides the ability to suppress the expression of
genes which trigger tumor development, siRNA can al-
so directly activate the expression of SOCS1 gene and
induce antitumor immune response. This property pro-
vides siRNA a great potential to be used in genetic the-
rapy of cancer.
Conclusions. After inoculation of Guerin’s carci-
noma to female-rats with simulated hypo- and hyper-
thyroidal states the proliferation of tumor cells is more
active in the group of animals with experimental hypo-
thyroidism.
The siRNA trasfection leads to the inhibition of tu-
mor growth in animals with both hypo- and hyperthy-
roidism, but this process is more active at hypothy-
roidism.
The prospects for further research are associated
with assessment of a possibility to use siRNA transfec-
tion for control and activation of apoptosis in an expe-
rimental model of tumorogenesis.
Â. Ì. Çàïîðîæàí, Ã. Ñ. Ìàðèíþê, O. Ë. Õîëîäêîâà,
Â. Â. Áóáíîâ, Ä. Þ. Àíäðîíîâ
Îö³íêà ìîæëèâîñò³ ñóïðåñ³¿ ïóõëèííîãî ðîñòó ³ç
âèêîðèñòàííÿì òðàíñôåêö³¿ ³íòåðôåðóþ÷èõ ÐÍÊ SOCS1
íà ïðèêëàä³ åêñïåðèìåíòàëüíî¿ ìîäåë³ óòâîðåííÿ ïóõëèíè
çà çì³íåíî¿ ôóíêö³¿ ùèòîïîä³áíî¿ çàëîçè
Ðåçþìå
Ìåòà. Îö³íèòè âïëèâ òðàíñôåêö³éíî ââåäåíî¿ siÐÍÊ íà ðîçâèòîê
ïóõëèíè çà óìîâ åêñïåðèìåíòàëüíî¿ ïàòîëîã³¿ ùèòîïîä³áíî¿ çàëî-
çè. Ìåòîäè. Åêñïåðèìåíòè âèêîíóâàëè íà ñàìèöÿõ ùóð³â ìàñîþ
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180 ± 20 ã. Òâàðèí ðîçä³ëåíî íà ï’ÿòü ãðóï: IA ³ IÁ – ùóðè ç ìîäåëü-
îâàíèìè ã³ïî- ³ ã³ïåðòèðåîçîì òà ïåðåâèòîþ êàðöèíîìîþ Ãåðå-
íà, IIA ³ IIÁ – ç ìîäåëüîâàíèìè ã³ïî- ³ ã³ïåðòèðåîçîì òà ïåðåâè-
òîþ êàðöèíîìîþ Ãåðåíà ó êîìïëåêñ³ ç òðàíñôåêö³éíî ââåäåíîþ
siÐÍÊ, ²²² – ç ïåðåâèòîþ êàðöèíîìîþ Ãåðåíà ó êîìïëåêñ³ ç òðàíñ-
ôåêö³éíî ââåäåíîþ siÐÍÊ. Âèì³ðþâàëè îðòîãîíàëüí³ ðîçì³ðè ïóõ-
ëèíè. Ïðîâîäèëè ã³ñòîëîã³÷í³ òà ³ìóíîã³ñòîõ³ì³÷í³ äîñë³äæåííÿ
çðàçê³â ïóõëèíè. Ðåçóëüòàòè. Ïîêàçàíî, ùî ³íã³áóâàëüíèé âïëèâ
êîðîòêèõ ³íòåðôåðóþ÷èõ ÐÍÊ á³ëüøîþ ì³ðîþ ïðîÿâëÿºòüñÿ çà
ã³ïîòèðåî¿äíîãî ñòàíó, ùî ñâ³ä÷èòü ïðî âàæëèâó ðîëü ãîðìîí³â
ùèòîïîä³áíî¿ çàëîçè ó ðåãóëÿö³¿ åêñïðåñ³¿ ãåí³â, êîíòðîëþþ÷èõ
êë³òèííèé öèêë. Îáãîâîðþºòüñÿ éìîâ³ðí³ñòü çàëåæíîñò³ ïåðåâà-
æàííÿ íåêðîá³îòè÷íèõ ïðîöåñ³â òà õàðàêòåðíèõ çì³í ó ñóäèíàõ
â³ä ä³¿ òèðåî¿äíèõ ãîðìîí³â íà àíã³îãåíåç ³ ïðîë³ôåðàòèâí³ ïðîöå-
ñè. Âèñíîâêè. Òðàñôåêö³ÿ siÐÍÊ ïðèçâîäèòü äî ïðèãí³÷åííÿ ïóõ-
ëèííîãî ðîñòó ó òâàðèí ÿê ç ã³ïî-, òàê ³ ç ã³ïåðòèðåîçîì, ïðîòå
àêòèâí³øå öåé ïðîöåñ ïðîò³êàº ïðè ã³ïîòèðåî¿äíîìó ñòàí³.
Êëþ÷îâ³ ñëîâà: òðàíñôåêö³ÿ, s³ÐÍÊ, åêñïåðèìåíòàëüíà ìî-
äåëü, ã³ïîòèðåîç, ã³ïåðòèðåîç.
Â. Ì. Çàïîðîæàí, À. Ñ. Ìàðèíþê, Å. Ë. Õîëîäêîâà,
Â. Â. Áóáíîâ, Ä. Þ. Àíäðîíîâ
Îöåíêà âîçìîæíîñòè ñóïðåññèè îïóõîëåâîãî ðîñòà ñ
èñïîëüçîâàíèåì òðàíñôåêöèè èíòåðôåðèðóþùèõ ÐÍÊ SOCS1
íà ïðèìåðå ýêñïåðèìåíòàëüíîé ìîäåëè îáðàçîâàíèÿ
îïóõîëè ïðè èçìåíåííîé ôóíêöèè ùèòîâèäíîé æåëåçû
Ðåçþìå
Öåëü. Îöåíêà âëèÿíèÿ òðàíñôåêöèîííî ââåäåííîé siÐÍÊ íà ðàç-
âèòèå îïóõîëè â óñëîâèÿõ ýêñïåðèìåíòàëüíîé ïàòîëîãèè ùèòî-
âèäíîé æåëåçû. Ìåòîäû. Ýêñïåðèìåíòû ïðîâîäèëè íà ñàìêàõ
êðûñ ìàññîé 180 ± 20 ã. Æèâîòíûõ ðàçäåëèëè íà ïÿòü ãðóïï: IA è
IÁ – êðûñû ñ ìîäåëèðîâàííûìè ãèïî- è ãèïåðòèðåîçîì è ïåðåâè-
òîé êàðöèíîìîé Ãåðåíà, IIA è IIÁ – ñ ìîäåëèðîâàííûìè ãèïî- è ãè-
ïåðòèðåîçîì è ïåðåâèòîé êàðöèíîìîé Ãåðåíà â êîìïëåêñå ñ
òðàíñôåêöèîííî ââåäåííîé siÐÍÊ, III – êîíòðîëüíàÿ ãðóïïà ñ ïå-
ðåâèòîé êàðöèíîìîé Ãåðåíà â êîìïëåêñå ñ òðàíñôåêöèîííî ââå-
äåííîé siÐÍÊ. Èçìåðÿëè îðòîãîíàëüíûå ðàçìåðû îïóõîëè. Îñóùå-
ñòâëÿëè ãèñòîëîãè÷åñêèå è èììóíîãèñòîõèìè÷åñêèå èññëåäîâà-
íèÿ îáðàçöîâ îïóõîëè. Ðåçóëüòàòû. Ïîêàçàíî, ÷òî èíãèáèðóþ-
ùåå âëèÿíèå êîðîòêèõ èíòåðôåðèðóþùèõ ÐÍÊ â áîëüøåé ñòå-
ïåíè ïðîÿâëÿåòñÿ ïðè ãèïîòèðåîèäíîì ñîñòîÿíèÿ, ÷òî óêàçûâà-
åò íà âàæíóþ ðîëü ãîðìîíîâ ùèòîâèäíîéæåëåçû â ðåãóëÿöèè ýêñ-
ïðåññèè ãåíîâ, êîíòðîëèðóþùèõ êëåòî÷íûé öèêë. Îáñóæäàåòñÿ
âåðîÿòíîñòü çàâèñèìîñòè ïðåîáëàäàíèÿ íåêðîáèîòè÷åñêèõ ïðî-
öåññîâ è õàðàêòåðíûõ èçìåíåíèé â ñîñóäàõ îò âëèÿíèÿ òèðåîèä-
íûõ ãîðìîíîâ íà àíãèîãåíåç è ïðîëèôåðàòèâíûå ïðîöåññû. Âû-
âîäû. Òðàíñôåêöèÿ siÐÍÊ ïðèâîäèò ê óãíåòåíèþ îïóõîëåâîãî
ðîñòà óæèâîòíûõ êàê ñ ãèïî-, òàê è ñ ãèïåðòèðåîçîì, îäíàêî áî-
ëåå àêòèâíî ýòîò ïðîöåññ ïðîòåêàåò ïðè ãèïîòèðåîèäíîãî ñî-
ñòîÿíèè.
Êëþ÷åâûå ñëîâà: òðàíñôåêöèÿ, s³ÐÍÊ, ýêñïåðèìåíòàëüíàÿ
ìîäåëü, ãèïîòèðåîç, ãèïåðòèðåîç.
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